Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT03915236
Other study ID # MON4STRAT
Secondary ID 2018-000450-21
Status Terminated
Phase N/A
First received
Last updated
Start date February 18, 2019
Est. completion date July 29, 2019

Study information

Verified date April 2019
Source Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Antibacterial drugs are facing increasing limitations in terms of effectiveness due to emergence resistance. Improved antibacterial drug monitoring approaches are particularly needed in nosocomial infections occurring in ICU patients, including ventilator-associated pneumonia and ventilator-associated tracheobronchitis, where decreased susceptibility of the etiological organisms is observed worldwide and pharmacokinetic alterations frequently observed.

No routine drug monitoring is available for betalactams at the point of care in a useful time frame (i.e., within a few hours after having collected the blood specimens).

The purpose of this study is to compare MON4STRAT approach for reaching and maintaining a meropenem pre-determined PK-PD target when compared to conventional meropenem dose.


Recruitment information / eligibility

Status Terminated
Enrollment 7
Est. completion date July 29, 2019
Est. primary completion date July 8, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Males and non-pregnant, non-lactating females, 18 years of age or older

2. Currently intubated and mechanically-ventilated subjects in the ICU

3. Suspicion of lower respiratory tract infection

4. Presence of Gram-negative organism(s) by Gram stain OR by culture of pre-therapy respiratory specimen (eg, endotracheal aspirate [ETA], bronchoalveolar lavage [BAL], or mini-BAL) OR previous colonization 48 h before screening.

5. Initial empiric antimicrobial meropenem regimen

6. At least two risk factors for multidrug-resistant organisms

7. Provision of written informed consent by the subject or a family member or a close relative or waiver of consent.

Exclusion Criteria:

1. Subjects who have received antibiotic therapy for Gram-negative LRT infection for = 36 hours at the time of randomization

2. Subjects with known or suspected type 1 hypersensitivity to beta-lactam and/or cephalosporin

3. Subjects taking valproic acid for a seizure disorder

4. Subjects who have had a left hemisphere stroke within five days and there is an increased risk of fatal brain oedema

5. Subjects who have cystic fibrosis, human immunodeficiency virus (HIV) infection with CD4 count <100 cell/mm3 or invasive fungal infection of the lung

6. Neutropenia (ANC < 103 neutrophils/mm3)

7. Bone marrow transplant.

8. Subjects who have been on mechanical ventilation for >28 days

Study Design


Related Conditions & MeSH terms


Intervention

Device:
MON4STRAT Strategy
Meropenem infusion guided by daily Therapeutic Drug Monitoring (adjusted in order to reach predetermined PK/PD targets) using MON4STRAT device.
Other:
Control group
Meropenem 1 gram infused every 8 hours over 30 minutes, consistent with standard-of-care treatment and published guidelines. Meropenem doses will be modified according to SmPC recommendations.

Locations

Country Name City State
Belgium Université Libre de Bruxelles Bruxelles
France Pitié Salpêtrière Hospital Paris
Spain Hospital Ramón y Cajal Madrid

Sponsors (1)

Lead Sponsor Collaborator
Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal

Countries where clinical trial is conducted

Belgium,  France,  Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary To document the superiority of the MON4STRAT approach for reaching and maintaining a meropenem pre-determined PK-PD target when compared to conventional therapies. The proportion of time from day 1 after randomization to end of therapy (EOT) in which the free meropenem trough concentration in serum was maintained above 8 mg/L or above 4 x MIC if antibiotic MIC > 2 and = 8 mg/L, without exceeding 140 mg/L at peak level, as determined by a method of reference (HPLC). During meropenem treatment: Day1 to Day 7
Secondary Clinical and microbiological response rates Test of cure (TOC) visit (7 to 10 days after last study drug infusion)
Secondary Time to LRT bacterial eradication, as assessed by follow-up cultures of ETA Days 3, 5, 7 of treatment and at the end of treatment (EOT) visit
Secondary All-cause mortality Day 14 and day 28
Secondary ICU and hospital length of stay Up to day 28
Secondary Number of mechanical ventilation-free days, defined as the number of days of unassisted breathing Up to day 28
See also
  Status Clinical Trial Phase
Recruiting NCT06016244 - Safe, Effective and Cost-Effective Oxygen Saturation Targets for Children and Adolescents With Respiratory Distress: a Randomized Controlled Trial N/A
Recruiting NCT03391076 - The Clinical Value of FA in AHLRI Patients N/A
Completed NCT03694392 - Flublok v. Standard Dose Vaccine Effectiveness Among Kaiser Permanente Northern California Adults 18-64 Years
Completed NCT01952470 - Preliminary Study of Dornase Alfa to Treat Chest Infections Post Lung Transplant. Phase 2
Recruiting NCT02929680 - Clinical Evaluation of FilmArray LRTI Panel N/A
Completed NCT02454114 - HOME FIRST Pilot: a Study of Early Supported Discharge in Patients With Lower Respiratory Tract Infections N/A
Completed NCT01931254 - Assess a Diagnostic Tool to Distinguish Between Bacterial and Viral Infection N/A
Completed NCT00975780 - A Trial to Reduce Pneumonia in Nursing Home Residents Phase 3
Completed NCT00350987 - Procalcitonin Guided Antibiotic Therapy and Hospitalisation in Patients With Lower Respiratory Tract Infections: The "ProHOSP" Study N/A
Completed NCT00420966 - Utilization and Compliance of Respiratory Syncytial Virus Monoclonal Antibody Therapy
Recruiting NCT06210282 - The Effect of Focused Lung Ultrasonography on Antibiotic Prescribing in General Practice N/A
Recruiting NCT05110261 - Evaluate the Safety and Efficacy of Nirsevimab in Healthy Preterm and Term Infants in China Phase 3
Recruiting NCT01985620 - The Impact of a Short Intervention During RSV Prophylaxis on Influenza Vaccination Rate. N/A
Recruiting NCT05374070 - Antiviral Activity of Oral Probiotics N/A
Recruiting NCT03808922 - Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study Phase 3
Not yet recruiting NCT03846401 - Bronchoscopy in Lower Respiratory Tract Infection in Respiratory Intensive Care Unit
Completed NCT01048073 - Non-influenza Etiologies of Acute Respiratory Illness in Southeast Asia N/A
Completed NCT00707941 - Oseltamivir Randomised Controlled Efficacy Trial Phase 3
Recruiting NCT03446534 - The Norwegian Antibiotics for Pneumonia in Children Study Phase 4
Completed NCT04311320 - A Low-Resource Oxygen Blender Prototype for Use in Modified Bubble CPAP Circuits N/A